Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients

This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and efficacy of Bisthianostat in refractory or recurrent multiple myeloma patients.

Study Overview

• Status: Unknown
• Conditions: Refractory Multiple Myeloma; Recurrent Multiple Myeloma
• Intervention / Treatment: Drug: Bisthianostat

Detailed Description

This is a first-in-human, single center, open-label, single arm, dose escalating phase I study. This study will be conducted in 3 parts.

Phase A : Patients will receive single dose of bisthianostat to evaluate the single-dose pharmacokinetics and safety.

Phase B: After single-dose phase, patients will receive multiple dose bisthianostat for 4 weeks on day 1,4,11,14,18,21,25,28 to evaluate the multiple-dose pharmacokinetics and safety

Phase C: Patients will continue on the study if they benefit from the drug and not experience any serious side effects.

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200127
      • Recruiting
      • RenJi Hospital
      • Contact: Hou Jian; Phone Number: 00862158752345; Email: hou.jian@renji.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosed as stage II or III (Durie-Salmon Staging System) multiple myeloma with disease progression or recurrence after at least two cycles of systemic antimyeloma treatment.
• Serum M protein≥ 5.0g / L, or urine M protein ≥ 200mg / 24h, or serum free light chain ≥ 200mg / L.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2.
• Expected survival of ≥3 months.
• Female participants of childbearing potential should have negative urine pregnancy test in screening period (accept previous test result within 14 days before screening), and must agree to adopt effective contraceptive measures within 14 days before receiving first dose of study drug, during the treatment period and within 28 days after final dose of study drug.
• Male participants must agree to adopt effective contraceptive measures and not allowed to donate sperms during the treatment period, and within 28 days after final dose of study drug.
• Hemoglobin ≥ 80 g/L, Platelet≥50×109/L (50,000/mm3), Absolute Neutrophil Count≧1.0×109/L (1000 cells/mm3), Prothrombin time(PT) and activated partial thromboplastin time ≤ 2 x Upper Limit of Normal (ULN)
• AST or ALT ≤ 1.5 x ULN, total bilirubin≤ 1.5 x ULN;
• Serum Creatinine ≤ 1.5 x ULN, glomerular filtration rate≥ 50 ml/min;
• NYHA Class I or II
• Written informed consent obtained prior to participation in the study

Exclusion Criteria:

• Pregnant or lactating women.
• Non-secretory multiple myeloma patients.
• Plasma cell leukemia patients.
• Received any anti-cancer medication or experimental drugs against multiple myeloma within 1 week before first dose of bisthianostat, any experimental treatment other than medication (eg. leukocyte donor/monocyte infusion) within 56 days before first dose of bisthianostat. Participation in any other drug or medical devices within 56 days before the study.
• Stem cell transplant planned on the following 28 days.
• Uncontrolled hypercalcemia after treatments, eg. saline infusion.
• Renal insufficiency required hemodialysis or peritoneal dialysis.
• NCI-CTCAE grade 2 Peripheral Neuropathy.
• Serious heart disease in the past 6 months, including angina requiring surgery, uncontrolled hypertension after anti-hypertensive treatments (Systolic blood pressure> 160 mmHg, Diastolic blood pressure>90mmHg); Myocardial infarction; Grade II-IV congestive heart failure; unstable angina.
• HIV, HCV or HBV (HBV-DNA > 20 IU/mL) infection.
• Patients with any other prior malignancy, except for skin basal cell carcinoma, cervical carcinoma in situ, breast carcinoma in situ, skin squamous cell carcinoma that have been treated and controlled.
• Imaging evidences show tumors have involved main blood vessels and nerves.
• Patients with significant central nervous system lesions.
• Patients with mental illness.
• Patients with history of alcohol or drug abuse, patients with allergy to the active ingredient or excipients of study drug, and patients who are unable or unwilling to receive the intravenous administration.
• Active infection (Bacteria, fungi, virus etc), fever with body temperature > 38 ℃ for reasons unknown.
• Other situations that investigator considers it's inappropriate for patients to participate in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: SEQUENTIAL
• Masking: NONE

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: 100mg Bisthianostat; 100mg starting dose taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).	Drug: Bisthianostat; Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.; Other Names: CF367-C, CFH367-C, CF367, PY-1
EXPERIMENTAL: 200mg Bisthianostat; 200mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).	Drug: Bisthianostat; Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.; Other Names: CF367-C, CFH367-C, CF367, PY-1
EXPERIMENTAL: 400mg Bisthianostat; 400mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).	Drug: Bisthianostat; Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.; Other Names: CF367-C, CFH367-C, CF367, PY-1
EXPERIMENTAL: 600mg Bisthianostat; 600mg Bisthianostat taken orally on Day 1, 4,7,11,14,18,21,25 and 28 of each cycle(4 weeks).	Drug: Bisthianostat; Bisthianostat is a histone deacetylase inhibitor (HDAC inhibitor) for the treatment of multiple myeloma.; Other Names: CF367-C, CFH367-C, CF367, PY-1

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose of Bisthianostat	To determine the maximum tolerated dose of Bisthianostat in refractory or recurrent multiple myeloma patients.	Up to 24 months
Treatment-related adverse events considered as dose-limiting toxicity	To evaluate the severity of treatment-related AEs considered as dose-limiting toxicity.	During the first cycle (4 weeks)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Peak Plasma Concentration (Cmax)	To determine the Peak Plasma Concentration of Bisthianostat.	During the first cycle (4 weeks)
Area under the plasma concentration versus time curve (AUC)	To determine the Area under the plasma concentration versus time curve of Bisthianostat.	During the first cycle (4 weeks)
Time of Peak Concentration (Tmax)	To determine the time of peak concentration of Bisthianostat.	During the first cycle (4 weeks)
Half life (T1/2)	To determine the half-life of Bisthianostat.	During the first cycle (4 weeks)
Objective Response Rate	To evaluate the objective response rate in refractory or recurrent myeloma patients after bisthianostat treatments.	Up to 1 month after last dose
Incidence of adverse events related to treatments	To evaluate the incidence of adverse events that are related to treatments in refractory or recurrent myeloma patients	Up to 1 month after last dose
Incidence of laboratory abnormalities related to treatments	To evaluate the incidence of laboratory abnormalities that are related to treatments in refractory or recurrent myeloma patients	Up to 1 month after last dose

Collaborators and Investigators

• Sponsor: Shanghai Theorion Pharmaceutical Co Ltd.
• Collaborators: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
• Investigators: Principal Investigator: Jian Hou, MD, RenJi Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 25, 2018
• Primary Completion (ANTICIPATED): April 1, 2020
• Study Completion (ANTICIPATED): July 1, 2020

Study Registration Dates

• First Submitted: July 13, 2018
• First Submitted That Met QC Criteria: August 1, 2018
• First Posted (ACTUAL): August 7, 2018

Study Record Updates

• Last Update Posted (ACTUAL): September 19, 2019
• Last Update Submitted That Met QC Criteria: September 18, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Disease Attributes; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Multiple Myeloma; Neoplasms, Plasma Cell; Recurrence
• Other Study ID Numbers: CH-020PI

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No